Rh Pharmaceuticals

Rh Pharmaceuticals is a biotechnology company focused on the development and commercialization of specialized biologics for the treatment and prevention of Rh-related hematological conditions. The company's primary focus is on addressing Rh isoimmunization, a condition where a pregnant woman's immune system attacks the red blood cells of her fetus, leading to hemolytic disease of the newborn (HDN). Their portfolio typically includes Rho(D) Immune Globulin products and related plasma-derived therapies. Rh Pharmaceuticals aims to improve maternal-fetal health outcomes through high-quality manufacturing and distribution of these critical life-saving treatments.